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To describe Neisseria meningitidis strains in the Afri-
can meningitis belt in 2003, we obtained 2,389 oropharyn-
geal swabs at 5 monthly visits a representative population 
sample (age range 4–29 years) in Bobo-Dioulasso, Burkina 
Faso. A total of 152 carriage isolates were grouped, sero-
typed, and genotyped. Most isolates were NG:NT:NST se-
quence type (ST) 192 (63% of all N. meningitidis), followed 
by W135:2a:P1.5,2 of ST-11 (16%) and NG:15:P1.6 of ST-
198 (12%). We also found ST-2881 (W135:NT:P1.5,2), ST-
751 (X:NT:P1.5), and ST-4375 (Y:14:P1.5,2) but not sero-
groups A or C. Estimated average duration of carriage was 
30 days (95% conﬁ  dence interval 24–36 days). In the con-
text of endemic group W135 and meningococcal A disease, 
we found substantial diversity in strains carried, including 
all strains currently involved in meningitis in this population, 
except for serogroup A. These ﬁ  ndings show the need for 
large samples and a longitudinal design for N. meningitidis 
serogroup A carriage studies.
I
n the African meningitis belt, serogroup A of Neisseria 
meningitidis (NmA) is the most frequent cause of bacte-
rial meningitis. Since an epidemic in 1987, these invasive 
NmA strains have been identiﬁ  ed as belonging to clonal 
complex sequence type (ST)–5 (1). From 1980 through 
2000, meningococcal serogroup W135 (NmW135) was 
found in Africa only occasionally (2) and never as an epi-
demic strain. At the end of the 2001 epidemic season in 
Burkina Faso and Niger, however, similar proportions of 
cases caused by NmW135 and NmA were found (3). Dur-
ing a large epidemic in Burkina Faso in 2002, phenotype 
W135:2a:P1.5,2 was the predominant strain; this strain be-
longed to the ST-11 clonal complex (4), as did NmW135 
strains found in an outbreak among Hajj pilgrims in 2000. 
Since early 2003, NmW135 has gradually decreased, and 
in 2005 and 2006 NmA again predominated, with some 
NmW135 outbreaks in Uganda, Sudan, and Kenya (5,6).
Most published carriage studies on sub-Saharan Africa 
were conducted after outbreaks, with transversal design 
or with nonsystematic specimen collection. These studies 
often found a predominance of the outbreak strain. Our 
longitudinal study describes meningococcal phenotypes 
and genotypes circulating in an urban Burkina Faso popu-
lation 1 year after an N. meningitidis W135 epidemic, their 
dynamics during a nonepidemic meningitis season, and 
the carriage prevalence of disease-causing strains in the 
healthy population.
Methods
Recruitment and Swab Collection
Methods, population characteristics, and 4-month car-
riage prevalence by serogroup have been previously report-
ed (7). The study was reviewed and approved by the Eth-
ics Committee of Centre Muraz, Bobo-Dioulasso, Burkina 
Faso, and the Comité de Vigilance of Pasteur Institute, 
Paris. Brieﬂ  y, after written informed consent was obtained 
from study participants or their guardians (for persons <18 
years of age), a random sample of the healthy residents of 
urban Bobo-Dioulasso, Burkina Faso, were examined at 5 
clinic visits from February 3 to June 7, 2003. The sampling 
design required that 1 participant 4–14 years of age and 
1 participant 15–29 years of age were included from each 
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selected compound (community of households). At all 5 
visits, swabs were taken from the posterior pharyngeal wall 
through the mouth by using cotton-tipped sterile swabs, 
which were streaked immediately onto plates containing 
selective medium. The plates were stored immediately in 
an atmosphere of 5% CO2 at room temperature for a maxi-
mum of 2 hours until incubation at 37°C. 
Microbiologic Analyses
N.  meningitidis strains from incubated plates were 
isolated and identiﬁ  ed by using established bacteriologic 
methods, following recommendations of the World Health 
Organization when applicable (8).  N.  lactamica isolates 
were also cultured and identiﬁ  ed. Conﬁ  rmation and geno-
group prediction of N. meningitidis isolates was conducted 
on the basis of PCR testing as previously described (9,10). 
All groupable N. meningitidis isolates and a subset of non-
groupable isolates were further tested with immune serum 
for serogroup conﬁ  rmation.
Serotypes and serosubtypes were determined by using 
monoclonal antibody kits obtained from the National In-
stitute of Public Health and the Environment (Bilthoven, 
the Netherlands) by the whole-cell enzyme immunoassay 
technique, as previously described (11). Chromosomal 
DNA restriction patterns were analyzed by pulsed-ﬁ  eld 
gel electrophoresis (PFGE). Whole chromosome DNA 
macrorestriction fragments generated by digestion with 
SpeI endonuclease were separated by PFGE as previously 
described (12). DNA fragments were separated by using a 
Chef-DR II system (Bio-Rad Laboratories, Hercules, CA, 
USA). PFGE ﬁ  ngerprint patterns were compared by using 
the criteria of Tenover et al. (13).
Multilocus sequence typing (MLST) was performed 
on a subset of 53 isolates chosen to represent different 
PFGE variants of different serogroups (14). Fragments 
from 7 housekeeping genes (abcZ, adk, aroE, fumC, gdh, 
pdhC, and pgm) were used for typing, as given on the Neis-
seria MLST website (http://pubmlst.org/neisseria/). After 
DNA preparation and ampliﬁ  cation by PCR, each locus 
sequence was analyzed on an ABI Prism 3100 DNA se-
quencer (Applied Biosystems, Foster City, CA, USA). Se-
quence analysis was performed by using Vector NTI suite 
software (InforMax, Bethesda, MD, USA). The sequences 
were compared with existing alleles on the Neisseria MLST 
website for determination of allele numbers, STs, and clon-
al complexes of the isolate. After internal validation tests, 
strains that had the same PFGE proﬁ  le were considered to 
belong to the same ST, and thus were deﬁ  ned as having the 
same ST (Figures 1, 2).
Estimation of Carriage Duration
Mean duration of carriage and 95% conﬁ  dence inter-
vals (CIs) were calculated by the truncated observations 
method described by de Wals and Bouckaert (15). We 
assumed that isolates with identical phenotypes and gen-
otypes collected from a person at consecutive visits, and 
only those, indicated an ongoing carriage event.
Results
A total of 488 persons were included in the study; 
>96% were seen at each respective visit. Eighteen percent 
of the population carried a meningococcus at least once 
during the study. All genogroupable isolates could be se-
rogrouped. The 152 meningococcal isolates were attrib-
uted  to  serogroups  NmW135  (n  =  28),  NmX  (n  =  5),  NmY                    
(n = 3), and nongroupable, autoagglutinable, or polyagglu-
tinable Nm (n = 116). No NmA, NmB, or NmC were found 
(Table 1).
Among the 151 meningococcal isolates submitted 
for serotyping, most could not be serotyped or serosub-
typed with existing antibodies (n = 98, 65%). Serotype 2a:
P1.5,2 (n = 17, 11%) and 15:P1.6 (n = 16, 11%) were the 
most frequently found serotypes, followed by NT:P1.5,2 
Figure 1. Pulsed-ﬁ   eld gel electrophoresis (PFGE) analysis of 
chromosomal DNA from pharyngeal meningococcus isolates         
(stained with ethidium bromide). Whole chromosome DNA 
macrorestriction fragments were generated by digestion with 
endonuclease SpeI. Shown are examples of sequence type (ST) 
prediction by PFGE in carried meningococci and diversity among 
STs. S, isolates tested by multilocus sequence typing (MLST).  Lanes 
λ (arrows), PFGE marker I (Boehringer Mannheim, Mannheim, 
Germany); lane A, ST-2881, meningitis case isolate, Niger 2003; 
lanes 101, 102, and 103, ST-11, W135:2a:P1.5,2; lanes 104 and 
105, ST-2881, W135:NT:P1.5,2; lane 106, ST-4151, W135:NT:
P1.5,2; lane 107, ST-112000, W135:NT:P1.5,2; lanes 108–116, ST-11, 
W135:2a:P1.5,2; lane B, meningitis case isolate, ST-11, Niger 2003. 
Isolates 101 and 107 were identiﬁ  ed as ST-11 by MLST. Isolates 
102, 103, 108, 109, and 111–116 are indistinguishable from isolate 
101 and are therefore considered ST-11. The 19 ST-11 isolates had 
4 different PFGE patterns, of which 3 are represented by isolates 
101, 107, and 110. The pattern of isolate 107 is indistinguishable 
from the 2000 Hajj epidemic strain (not shown).Meningococcal Carriage, Burkina Faso, 2003
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(n = 11, 7%), NT:P1.5 (n = 6, 4%), and 14:P1.5,2 (n = 3, 
2%) (Figure 3, Table 1).
Among the 151 isolates analyzed by MLST or PFGE, 
most were ST-192 (n = 96, 63%), followed by ST-11 
(n = 19, 13%), ST-198 (n = 13, 9%), and ST-2881 (n = 
8, 6%, including 1 strain with the single locus variant ST-
4151) (Table 1). Other STs represented <5% of the carriage 
strains and included ST-4426 (in the clonal complex ST-
198), ST-751 (including the single locus variant ST-4376), 
ST-4375 (in the clonal complex ST-23), and ST-4377.
Serogroup W135 was mostly found in combination 
with serotype 2a:P1.5,2 and genotype ST-11. Serogroup 
X was found with NT:P1.5, ST-751, and serogroup Y was 
found with 14:P1.5,2, ST-4375 (Table 1).
Diversity among STs
The 19 isolates belonging to ST-11 showed moderate 
diversity in restriction patterns (Figure 1). Three (16%) 
isolates found in February 2003, among them 2 isolates 
with phenotype W135:NT:P1.5,2, were indistinguishable 
from the 2000 Hajj outbreak strain, and 1 (5%) isolate 
each showed 1- and 2-band differences from the 2000 Hajj 
strain. The other 14 ST-11 isolates (74%), among them an 
isolate with phenotype NG:2a:P1.5,2, showed a 6-band dif-
ference from the 2000 Hajj strain.
The 8 ST-2881 isolates belonged to 1 clone with a 0- to 
2-band difference between them. Although most of the ST-
2881 isolates belonged to group W135, their PFGE patterns 
were unrelated to ST-11 isolates in group W135; they were 
closely related to ST-2881 invasive strains of serogroup 
W135 found in 2003 in Niger (16).
Among the 96 ST-192 isolates, 86 had interpretable 
results by PFGE, which showed considerable diversity in 
restriction patterns (Figure 2). Of these isolates, 41 (48%) 
were indistinguishable from each other and 10 (12%), 
among them the isolate with phenotype W135:NT:NST, 
were closely related with 1- to 3-band differences. Thir-
ty-one isolates (36%) were possibly related to the central 
Figure 2. Pulsed-ﬁ   eld gel electrophoresis (PFGE) analysis of 
chromosomal DNA from pharyngeal meningococcus isolates   
(stained with ethidium bromide). Whole chromosome DNA 
macrorestriction fragments were generated by digestion with 
endonuclease SpeI. Shown are examples of sequence type (ST) 
prediction by PFGE in carried meningococci and diversity among 
STs types. S, isolates tested by multilocus sequence typing 
(MLST). Lanes λ (arrows) PFGE marker I (Boehringer Mannheim, 
Mannheim, Germany); lane C, ST-2881, meningitis case isolate, 
Niger 2003; lanes 155, 166, and 192–194, ST-192, NG:NT:NST; 
lane 195, ST-198, NG:15:P1.6; lanes 196–198, ST-192, NG:NT:
NST; lane 199, isolate unrelated to the presented study; lanes 
200–205, ST-192, NG:NT:NST; lane D, meningitis case isolate, ST-
11, Niger 2003. Isolates 192, 193, 194, 196, 198, and 204 were 
identiﬁ  ed as ST-192 by MLST. Isolates 197, 200, 201, 202, and 
203 are indistinguishable from isolate 196 and are thus considered 
ST-192. ST-192 isolates from this study had 10 different PFGE 
patterns, of which 6 are represented by isolates 155, 166, 192, 194, 
196, and 204.
Table 1. Characterization of 152 meningococcal isolates, Bobo-Dioulasso, Burkina Faso, 2003* 
Sequence type (ST) 
No. isolates
(% ST) 
No. tested by 
MLST Phenotype 
No. (%) ST isolates 
with phenotype 
ST-192 96 (63)  40 NG:NT:NST  95 (63) 
W135:NT:NST 1 (1)
ST-11 19 (13)  5 W135:2a:P1.5,2  16 (11) 
W135:NT:P1.5,2 2 (1)
NG:2a:P1.5,2 1 (1)
ST-198 13 (9)  3 NG:15:P1.6  12 (8) 
W135:15:P1.6 1 (1)
ST-4426 (clonal complex ST-198)  2 (1)  2 NG:15:P1.6  2 (1) 
ST-2881 8 (5)  2 W135:NT:P1.5,2  8 (5) 
ST-4151 (single locus variant of ST-2881)  1 (1)  1 W135:NT:P1.5,2  1 (1) 
ST-751 5 (3)  3 X:NT:P1.5 5 (3) 
ST-4376 (single locus variant of ST-751)  1 (1)  1 NG:NT:P1.5  1 (1) 
ST-4375 (clonal complex ST-23)  3 (2)  1 Y:14:P1.5,2  3 (2) 
ST-2049 1 (1)  1 NG:15:P1.6  1 (1) 
ST-4377 2 (1)  2 NG:NT:NST  2 (1) 
Not tested  1 (1)  – NG: Not determined  1 (1) 
Total 152 (100) 61 152  (100) 
*MLST, multilocus sequence typing. NG includes nongroupable, autoagglutinable, and polyagglutinable strains. RESEARCH
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clone (4- to 6-band difference), and 4 (5%) were unrelated 
(>7-band difference).
Carriage Dynamics
The gradual increase in carriage point prevalence of 
any Nm from 3.5% in February to 9.9% in May–June was 
caused by an increase in ST-192 with a phenotype of NG:
NT:NST (Figure 3). The number of isolates of this geno-
type and phenotype at each of the 5 visits was 7, 8, 15, 26, 
and 27, respectively.
Among the 84 persons who carried meningococci dur-
ing >1 visit, half (n = 42) were carriers at only 1 visit and 
half at multiple visits. Of the 42 persons with meningo-
coccal carriage at several visits, 21 always had the same 
strain (Table 2) and 19 had different strains (Table 3). 
The latter group carried <3 different strains during the 4 
months of observation, and 4 persons had the same strain 
on multiple occasions but with interruption. Twenty-seven 
persons (32% of all carriers) had the same strain >2 times 
at subsequent visits. The mean duration of carriage for 
all serogroups was estimated as 30 days (95% CI 24–36 
days). Estimated mean carriage duration was 20 days (95% 
CI 15–23 days) for NmW135 and 34 days (95% CI 27–42 
days) for nongroupable strains. The estimated mean dura-
tion of overall Nm carriage increased with the increasing 
prevalence of nongroupable strains toward the end of the 
meningitis season: 21 days (95% CI 18–24 days) during 
February–April compared with 35 days (95% CI 28–43 
days) during April–June.
In addition to the 152 meningococci, 103 N. lactamica 
were isolated. Prevalence of N. lactamica was highest in 4 
to 8-year-old children and increased gradually from 5.5% 
(95% CI 2.1%–13.2%) at the ﬁ  rst visit to 16.1% (95% CI 
10.9%–23.1%) at the last visit. For persons 9–18 years of 
age, prevalence of N. lactamica carriage varied from 2% to 
4% over the 5 visits; carriage for adults was >1.5%.
Discussion
This longitudinal carriage study in a healthy young 
population in the African meningitis belt describes the di-
versity of carried meningococcal serogroups, serotypes, 
and genotypes during a nonepidemic meningitis season. 
Eleven STs and 4 serogroup categories (including non-
groupable strains) were identiﬁ   ed. Parallel culture- and 
PCR-based meningitis surveillance in this population dur-
ing 2003 showed a high incidence of endemic meningococ-
cal disease (annual rate = 77/100,000 among persons <5 
years of age and 5/100,000 among persons >14 years of 
age). During February–April 2003, 9 cases of NmA men-
ingitis and 28 cases of NmW135 meningitis were found 
in urban Bobo-Dioulasso (435,000 inhabitants), as well as 
sporadic cases caused by serogroup X and nongroupable 
meningococci (Table 4) (5,17).
Despite frequent serogroup A disease, no serogroup A 
meningococcal carriage was found. NmA was likely circu-
lating at low levels during our study but not found because 
of low transmission density or short duration of NmA car-
riage, together with sample size limitation. Our study thus 
provides evidence for low prevalence of serogroup A car-
riage in nonepidemic conditions, which is similar to results 
of a study in Nigerian schoolchildren (18). This ﬁ  nding is 
useful for assessment of group A conjugate meningococ-
cal vaccines by carriage studies. To show a reduction in 
NmA carriage prevalence after vaccination, as was recently 
reported from the United Kingdom for group C conjugate 
vaccine (19), studies need to include several thousand per-
sons to achieve appropriate statistical power.
Apart from NmA, all phenotypes and genotypes iso-
lated from meningococcal meningitis cases in this popula-
tion from 2000 through 2005 (Table 5) were represented 
Figure 3. Serogroups (A), serotypes (B), and sequence types (C) 
of 152 meningococci carried by 488 persons obtained at 5 monthly 
study visits from February through June 2003, Bobo-Dioulasso, 
Burkina Faso. NG, nongroupable; ST, sequence type.Meningococcal Carriage, Burkina Faso, 2003
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in this 4-month carriage study of 488 persons. This ﬁ  nding 
supports the use of carriage studies in nonepidemic condi-
tions for surveillance of meningococcal strains of speciﬁ  c 
serogroups. For surveillance of new genotypes expressing 
a group A capsule, however, disease surveillance will be 
more appropriate. For example, ST-2859, a new genotype 
that expresses group A capsule, has become a major menin-
gitis agent in Bobo-Dioulasso since 2002 (17). Our carriage 
study did not detect this development. In addition, results 
from localized carriage studies should not be generalized to 
West Africa and the African meningitis belt as a whole be-
cause only 4 of 7 serogroups and 5 of 15 genotypes found 
in meningococcal meningitis cases in the region during 
2000–2005 were represented in our carriage study.
During bacterial meningitis surveillance in the Bobo-
Dioulasso population in 2004, we observed 2 invasive 
strains whose genotypes had been associated with differ-
ent serogroups and serotypes in our carriage study 1 year 
earlier (Table 5). ST-11, which is usually associated with 
phenotype W135:2a:P1.5,2 in invasive strains, had pheno-
type Y:14:P1.5,2 (seen in ST-4375 carriage strains), and 
ST-4375, which is usually associated with phenotype Y:14:
P1.5,2, had phenotype W135:NT:P1.5,2 (seen in ST-11 
carriage strains). These ﬁ  ndings could be evidence for a 
Table 2. Analysis of 21 persons carrying the same meningococcal strain at 5 monthly visits, Bobo-Dioulasso, Burkina Faso, 2003 
Person Age, y  Visit 1  Visit 2 Visit 3 Visit 4 Visit 5
1 4 W135: ST-2881 W135: ST-2881 
2 6 NG:ST-192 NG:ST-192 NG:ST-192 
3 7 NG:ST-192 NG:ST-192  NG:ST-192 
4 8 NG:ST-192 NG:ST-192 
5 10 NG:ST-192 NG:ST-192 NG:ST-192 
61 1 NG:ST-192 NG:ST-192 
71 1 NG:ST-192 NG:ST-192 
8 12 NG:ST-192 NG:ST-192 NG:ST-192 
9 14 NG:ST-192 NG:ST-192 NG:ST-192 
10 14 NG:ST-192 NG:ST-192 
11 14 NG:ST-192 NG:ST-192 NG:ST-192 
12 15 NG:ST-192 NG:ST-192 
13 16 NG:ST-198 NG:ST-198 
14 17 NG:ST-192 NG:ST-192 
15 17 NG:ST-192 NG:ST-192 
16 18 NG:ST-192 NG:ST-192 NG:ST-192 
17 19 NG:ST-192 NG:ST-192  NG:ST-192 
18 20 NG:ST-192 NG:ST-192  NG:ST-192 
19 20 NG:ST-192 NG:ST-192 
20 22 NG:ST-192 NG:ST-192 
21 26 W135: ST-11 W135: ST-11
Table 3. Analysis of 19 persons carrying >1 meningococcal strain at 5 monthly visits, Bobo-Dioulasso, Burkina Faso, 2003 
Person Age, y  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5 
22 4 NG: ST-198 NG:ST-192  NG:ST-192 
23 5 W135: ST-11 NG:ST-192 NG:ST-192 
24 8 W135: ST-2881 NG:ST-4426 
25 8 X: ST-751  NG:ST-192  X: ST-751 
26 9 NG:ST-192 W135: ST-11
27 11 W135: ST-11  NG:ST-192  W135: ST-2881 
28 13 NG: ST-198 NG:ST-192  NG:ST-192 
29 14 NG: ST-198 NG:ST-192 
30 16 W135: ST-2881 Y:ST-4375 
31 18 W135: ST-11  NG:ST-2049  NG: ST-198  NG: ST-198 
32 18 NG:ST-11 W135: ST-2881  NG:ST-192 
33 18 NG:ST-192 NG: ST-198  NG:ST-192 
34 20 NG: ST-198  NG: ST-192  NG: ST-192 
35 21 W135: ST-11  NG:ST-192  W135: ST-11 
36 22 X: ST-751  NG: ST-198  NG:ST-192  X: ST-751 
37 22 X: ST-751  W135: ST-2881 
38 23 W135: ST-11 NG:ST-4377 NG:ST-192 
39 26 NG:ST-192 NG:ST-4377 
40 26 NG: ST-192 NG: ST-4426 RESEARCH
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capsular and serotype switch between co-colonizing me-
ningococci, as described by Swartley et al. (23). However, 
that report described only gene conversion for capsule ex-
pression, not for outer membrane protein (PorB) expres-
sion. The potential capacity of meningococci to exchange 
capsular plus subcapsular genes needs to be further evalu-
ated.
Our study and previous studies of meningococci in 
sub-Saharan Africa have shown a similar number of dif-
ferent serogroup categories, including nonserogroupable 
strains (18,24–26). However, assessing whether the genetic 
diversity we found is a new phenomenon is difﬁ  cult be-
cause most studies do not report genotypes of all isolates. 
Five ST strains expressed group W135 capsule in this pop-
ulation that was followed up over a 4-month period. This 
variation has not been reported for other meningococcal 
serogroups in sub-Saharan Africa but is consistent with 
results of a report on increasing genetic diversity of W135-
encapsulated strains in France since the Hajj-associated 
outbreak in 2000 (27). In contrast to NmW135, NmA has 
a relatively low genetic diversity, with only 6 genotypes 
found to express the A capsule over the past 30 years ([1]; 
http://pubmlst.org/neisseria). This difference between the 2 
serogroups suggests that NmW135 may not replace NmA 
as the major epidemic agent in the future. Nevertheless, 
the easy adoption of a W135 capsule by various genotype 
stains, in combination with infrequent immune induction 
by NmW135 carriage (7), may cause regular NmW135 out-
breaks to occur.
Nongroupable strains were predominant in our study 
and other carriage studies during nonepidemic conditions 
in Burkina Faso, Ghana, Europe, and the United States 
(20,24,28–31). In our study, nongroupable and nontypeable 
isolates were predominantly ST-192, which represented 
63% of all carried meningococci. Data from the Neisseria 
MLST website indicate that ST-192 isolates were present 
in The Gambia and Niger in the 1990s, but no published 
data are available on the dimension of prevalence of this 
strain in these or other countries. This strain deserves closer 
observation because in Bobo-Dioulasso during 2003 and 
2004, 3 persons were found with disease caused by non-
groupable ST-192 isolates. Unencapsulated strains rarely 
cause invasive disease and usually only among comple-
ment-deﬁ  cient persons (32). This may have occurred in the 
3 patients, whose complement status was not determined. 
However, the isolates from Bobo-Dioulasso also showed 
Table 4. Meningococci isolated during surveillance of acute 
bacterial meningitis, Bobo-Dioulasso, Burkina Faso, February–
April 2003 
Sequence type (ST)  Phenotype  No. cases 
ST-11 W135:2a:P1.5,2  28
ST-2859 (ST-5 complex)   A:4:P1.9 9
ST-751 X:NT:P1.5 1
ST-192 NG:NT:NST  2
Table 5. Overview of meningococci reported from meningitis patients in West Africa and the African meningitis belt, 2000–2005* 
Sequence type (ST)  Phenotype  Place and time of meningococcal disease cases 
ST-11 W135:2a:P1.5,2  Sporadic in Cameroon, Senegal, Burkina Faso, Central 
African Republic, Chad, Niger, and Ghana since 2003; 
epidemic and major seasonal agent in Burkina Faso
during 2002–2004 (including Bobo-Dioulasso) 
W135:NT:P1.5,2  Sporadic in Bobo-Dioulasso, 2004 
W135:2a:P1.2, W135:NT:P1.2 Sporadic in Niger, 2003 
Y:14:P1.5,2  Sporadic in Bobo-Dioulasso, 2004 
ST-1966 (ST-11 complex)  W135:2a:P1.5,2  Sporadic in Burkina Faso 
ST-2881 W135:NT:P1.5,2  Sporadic in Benin since 2003; 
major seasonal agent in Niger during 2003 
ST-5 A:4:P1.9, A:21:P1.9  Major seasonal agent in Niger, Senegal, and Burkina Faso 
during 2000–2001 
ST-7 (ST-5 complex)  A:4:P1.9, A:21:P1.9  Major seasonal agent and epidemic in Cameroon, Chad, 
Niger, Senegal, Benin, Burkina Faso, Ethiopia, and Nigeria 
ST-2859 (ST-5 complex)  A:4:P1.9, A:21:P1.9  Major seasonal agent and epidemic in Burkina Faso  
since 2003 (including Bobo-Dioulasso) 
ST-751 X:NT:P1.5, X:NT:P1.5,2  Sporadic in Burkina Faso (including Bobo-Dioulasso),
Niger, and Ghana 
ST-181 X:NT:P1.5 Sporadic in Niger 
ST-2880 Y:14:P1.5,2  Sporadic in Niger 
ST-4375 (ST-23 complex)  Polyagglutinable:14:P1.5,2  Sporadic in Bobo-Dioulasso, 2004 
W135:NT:P1.5,2  Sporadic in Bobo-Dioulasso, 2004 
ST-23 (ST-23 complex)  Y:14:NST  Sporadic in Senegal 
ST-32, ST-2496 (ST-32 complex), 
ST-291 (ST-41/44 complex) 
C:4:P1.16, B:4:P1.16, B:4: 
P1.7,16, B:4:P1.9 
Sporadic in Cameroon 
ST-192 NG:NT:NST  Sporadic in Bobo-Dioulasso, 2003 and 2004 
*Data were obtained from references 1,5,16,17,20–22, and the Neisseria multilocus sequencing typing website (http://pubmlst.org/ 
neisseria).Meningococcal Carriage, Burkina Faso, 2003
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enhanced capacity to escape human immune defenses (33), 
which would enable these isolates to cause invasive disease 
in immunocompetent persons.
In our study, carriage of the NG:NT ST-192 strain in-
creased from the early phase of the meningitis season to 
just past its end, as did carriage of N. lactamica in children. 
This ﬁ  nding may be an annual phenomenon that is associ-
ated with a decreasing meningitis incidence by late April 
(Figure 4), which would be caused by a reduced risk for 
infection or disease by virulent meningococci, given the in-
creased carriage prevalence of nongroupable meningococci 
(34). However, our data were from a small sample and only 
1 population during 1 meningitis season. A more system-
atic evaluation by longitudinal carriage studies in several 
African sites is needed to further explore this hypothesis.
Carriage during this study was dynamic and short-
lived compared with other studies in Europe (15,30,35). 
This ﬁ  nding emphasizes the need for a large sample size 
in cross-sectional carriage studies and the need for multiple 
assessment points over short intervals for studies on car-
riage association with risk factors or immune status. Esti-
mated carriage duration was longer for less virulent non-
groupable strains than for NmW135. This could be due to a 
more accentuated immune response to carriage of encapsu-
lated strains, although serologic evaluation during the same 
study suggested that the immune response to NmW135 car-
riage does not occur frequently (7).
In the context of hyperendemic NmW135 and NmA 
disease in Bobo-Dioulasso in 2003, we found a large di-
versity of phenotypes and genotypes in carried Nm strains 
(including all strains, except for serogroup A) that caused 
meningococcal meningitis in this population. NmW135 
showed substantial prevalence and high genetic diversity. 
These features distinguish this serogroup from NmA and 
indicate that, in combination with poor immune induction 
by carriage, this serogroup may be a potential epidemic 
agent. The absence of NmA during this nonepidemic men-
ingitis season and the pronounced dynamics of meningo-
coccal carriage emphasize the need for large samples and a 
longitudinal design for most carriage studies. By decreasing 
the risk for infection with a virulent clone, expansion of a 
nonvirulent clone in carriage toward the end of the menin-
gitis season may be 1 of the mechanisms causing a seasonal 
decrease in the incidence of meningococcal disease. 
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